• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

噬菌体治疗感染的挑战与机遇。

Challenges and opportunities of phage therapy for infections.

机构信息

The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan, China.

Department of Clinical Laboratory, The First People's Hospital of Yunnan Province, Kunming, Yunnan, China.

出版信息

Appl Environ Microbiol. 2024 Oct 23;90(10):e0135324. doi: 10.1128/aem.01353-24. Epub 2024 Sep 30.

DOI:10.1128/aem.01353-24
PMID:39345202
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11497816/
Abstract

Traditional antibiotics have been effective in many cases. However, the rise in multidrug-resistant bacteria has diminished their therapeutic efficacy, signaling the dawn of an era beyond antibiotics. The challenge of multidrug resistance in is particularly critical, with increasing global mortality and resistance rates. Therefore, the development of alternative therapies to antibiotics is urgently needed. Phages, which are natural predators of bacteria, have inherent advantages. However, comprehensive information on phages is lacking in current literature. This review aims to analyze and summarize relevant studies, focusing on the present state of phage therapy for infections. This includes an examination of treatment methodologies, associated challenges, strategies, new phage technologies, clinical trial safety and efficacy, regulatory issues, and future directions for phage therapy development. Enhancing phage technology is crucial for addressing the evolving threat of multidrug-resistant .

摘要

传统抗生素在许多情况下都很有效。然而,多重耐药菌的出现降低了它们的治疗效果,这标志着抗生素时代的结束。 的多重耐药性挑战尤其严峻,全球死亡率和耐药率不断上升。因此,迫切需要开发抗生素的替代疗法。噬菌体作为细菌的天然捕食者,具有内在的优势。然而,目前文献中缺乏关于 噬菌体的全面信息。本综述旨在分析和总结相关研究,重点关注噬菌体治疗 感染的现状。这包括检查治疗方法、相关挑战、策略、新型噬菌体技术、临床试验的安全性和疗效、监管问题以及噬菌体治疗发展的未来方向。增强噬菌体技术对于应对不断演变的多重耐药 威胁至关重要。

相似文献

1
Challenges and opportunities of phage therapy for infections.噬菌体治疗感染的挑战与机遇。
Appl Environ Microbiol. 2024 Oct 23;90(10):e0135324. doi: 10.1128/aem.01353-24. Epub 2024 Sep 30.
2
Potential of a phage cocktail in the treatment of multidrug-resistant Klebsiella pneumoniae pulmonary infection in mice.噬菌体鸡尾酒疗法治疗小鼠耐多药肺炎克雷伯菌肺部感染的潜力
BMC Microbiol. 2025 Mar 17;25(1):151. doi: 10.1186/s12866-025-03851-6.
3
Targeted phage hunting to specific clinical isolates is an efficient antibiotic resistance and infection control strategy.靶向噬菌体猎捕特定临床分离株是一种有效的抗生素耐药性和感染控制策略。
Microbiol Spectr. 2024 Oct 3;12(10):e0025424. doi: 10.1128/spectrum.00254-24. Epub 2024 Aug 28.
4
The potential use of bacteriophages as antibacterial agents against Klebsiella pneumoniae.噬菌体作为抗肺炎克雷伯菌抗菌剂的潜在用途。
Virol J. 2024 Aug 19;21(1):191. doi: 10.1186/s12985-024-02450-7.
5
Antibacterial effect of phage cocktails and phage-antibiotic synergy against pathogenic .噬菌体鸡尾酒和噬菌体-抗生素协同作用对致病菌的抗菌效果。
mSystems. 2024 Sep 17;9(9):e0060724. doi: 10.1128/msystems.00607-24. Epub 2024 Aug 21.
6
Revisiting therapeutic options against resistant klebsiella pneumoniae infection: Phage therapy is key.重新审视针对耐多药肺炎克雷伯菌感染的治疗选择:噬菌体疗法是关键。
Microbiol Res. 2025 Apr;293:128083. doi: 10.1016/j.micres.2025.128083. Epub 2025 Jan 31.
7
Bacteriophage Treatment Rescues Mice Infected with Multidrug-Resistant Klebsiella pneumoniae ST258.噬菌体治疗挽救感染多重耐药肺炎克雷伯菌 ST258 的小鼠。
mBio. 2021 Feb 23;12(1):e00034-21. doi: 10.1128/mBio.00034-21.
8
Phage M198 and Its Therapeutic Potential.噬菌体M198及其治疗潜力。
Viruses. 2025 Jan 15;17(1):115. doi: 10.3390/v17010115.
9
Phage cocktail amikacin combination as a potential therapy for bacteremia associated with carbapenemase producing colistin resistant Klebsiella pneumoniae.噬菌体鸡尾酒联合阿米卡星治疗产碳青霉烯酶多黏菌素耐药肺炎克雷伯菌菌血症的研究
Sci Rep. 2024 Nov 22;14(1):28992. doi: 10.1038/s41598-024-79924-9.
10
Characterization of novel phages KPAФ1, KP149Ф1, and KP149Ф2 for lytic efficiency against clinical MDR Klebsiella pneumoniae infections.新型噬菌体KPAФ1、KP149Ф1和KP149Ф2对临床耐多药肺炎克雷伯菌感染的裂解效率特性研究。
Microb Pathog. 2025 May;202:107440. doi: 10.1016/j.micpath.2025.107440. Epub 2025 Feb 28.

引用本文的文献

1
Microbial keratitis in the age of resistance: unlocking the therapeutic potential of phage therapy.耐药时代的微生物性角膜炎:挖掘噬菌体疗法的治疗潜力
Graefes Arch Clin Exp Ophthalmol. 2025 Sep 18. doi: 10.1007/s00417-025-06961-z.
2
Investigating the phenotypic alterations associated with hypermucoviscous hypervirulent Klebsiella pneumoniae during phage resistance development.研究噬菌体抗性发展过程中与高黏液性高毒力肺炎克雷伯菌相关的表型改变。
BMC Microbiol. 2025 Aug 22;25(1):528. doi: 10.1186/s12866-025-04268-x.
3
Breaking the resistance: integrative approaches with novel therapeutics against Klebsiella pneumoniae.突破耐药性:针对肺炎克雷伯菌的新型疗法综合方法
Arch Microbiol. 2024 Dec 26;207(1):18. doi: 10.1007/s00203-024-04205-y.

本文引用的文献

1
Personalized bacteriophage therapy outcomes for 100 consecutive cases: a multicentre, multinational, retrospective observational study.100 例连续病例的个体化噬菌体治疗结果:一项多中心、多国、回顾性观察研究。
Nat Microbiol. 2024 Jun;9(6):1434-1453. doi: 10.1038/s41564-024-01705-x. Epub 2024 Jun 4.
2
Successful phage-antibiotic therapy of implant-associated infection in a Siamese cat.暹罗猫种植体相关感染的噬菌体-抗生素治疗成功。
Vet Q. 2024 Dec;44(1):1-9. doi: 10.1080/01652176.2024.2350661. Epub 2024 May 10.
3
Therapeutic efficacy of a K5-specific phage and depolymerase against Klebsiella pneumoniae in a mouse model of infection.针对感染小鼠模型中肺炎克雷伯菌的 K5 特异性噬菌体和去聚合酶的治疗效果。
Vet Res. 2024 May 7;55(1):59. doi: 10.1186/s13567-024-01311-z.
4
Probing the interaction of bacteriophage as a biological agent to control the american foulbrood disease in honeybee.探究噬菌体作为一种生物制剂与蜜蜂美洲幼虫腐臭病之间的相互作用。
Saudi J Biol Sci. 2024 Jun;31(6):104002. doi: 10.1016/j.sjbs.2024.104002. Epub 2024 Apr 25.
5
Engineered Bacteriophage-Based Vaccine Remodels a Tumor Microenvironment and Elicits Potent Antitumor Immunity.基于工程噬菌体的疫苗重塑肿瘤微环境并引发强烈的抗肿瘤免疫。
ACS Nano. 2024 May 14;18(19):12194-12209. doi: 10.1021/acsnano.4c00413. Epub 2024 Apr 30.
6
The Medicinal Phage-Regulatory Roadmap for Phage Therapy under EU Pharmaceutical Legislation.欧盟药品立法下噬菌体治疗的药用噬菌体调控路线图。
Viruses. 2024 Mar 12;16(3):443. doi: 10.3390/v16030443.
7
Phage resistance in Klebsiella pneumoniae and bidirectional effects impacting antibiotic susceptibility.肺炎克雷伯菌的噬菌体耐药性及其对抗生素敏感性的双向影响。
Clin Microbiol Infect. 2024 Jun;30(6):787-794. doi: 10.1016/j.cmi.2024.03.015. Epub 2024 Mar 22.
8
Antibacterial and Anti-Biofilm Efficacy of Endolysin LysAB1245 against a Panel of Important Pathogens.内溶素LysAB1245对一组重要病原菌的抗菌及抗生物膜功效
Pharmaceuticals (Basel). 2024 Jan 25;17(2):155. doi: 10.3390/ph17020155.
9
Exploiting lung adaptation and phage steering to clear pan-resistant Pseudomonas aeruginosa infections in vivo.利用肺适应性和噬菌体导向清除体内泛耐药铜绿假单胞菌感染。
Nat Commun. 2024 Feb 20;15(1):1547. doi: 10.1038/s41467-024-45785-z.
10
Isolation and characterization of a novel temperate bacteriophage infecting Aeromonas hydrophila isolated from a Macrobrachium rosenbergii larvae pond.从罗氏沼虾幼体池塘中分离到一株温和噬菌体,并对其进行了分离和鉴定,该噬菌体可感染嗜水气单胞菌。
Virus Res. 2024 Jan 2;339:199279. doi: 10.1016/j.virusres.2023.199279. Epub 2023 Nov 23.